{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T06:41:34Z","timestamp":1697179294863},"reference-count":16,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2013,3,7]],"date-time":"2013-03-07T00:00:00Z","timestamp":1362614400000},"content-version":"vor","delay-in-days":1526,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2009,1]]},"abstract":"<jats:p>Taranabant, an orally active, potent, and highly selective CB\u20101 receptor inverse agonist, is being developed for the treatment of obesity. This randomized, placebo\u2010controlled, multiple\u2010dose, crossover study evaluated the effect of taranabant on the pharmacokinetics of ethinyl estradiol and norelgestromin in healthy women receiving \u22653 months of therapy with oral contraceptives. Nineteen participants with normal menstrual cycles received oral contraceptives on days 1 to 21 during 2 consecutive contraceptive cycles. Participants received taranabant 6 mg\/day or placebo on days 1 to 21 of each contraceptive cycle. Plasma samples were collected predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose on day 21 of each cycle for determination of AUC<jats:sub>0\u201324 h<\/jats:sub> and C<jats:sub>max<\/jats:sub> of ethinyl estradiol and norelgestromin. Lack of a clinically important effect was declared if the 90% confidence intervals for the geometric mean ratio of AUC<jats:sub>0\u201324 h<\/jats:sub> and C<jats:sub>max<\/jats:sub> in the absence and presence of taranabant were contained within the predefined bounds of (0.8, 1.25). The geometric mean ratios and 90% confidence intervals of ethinyl estradiol and norelgestromin, respectively, were 0.93 (0.87, 1.00) and 1.02 (0.96, 1.09) for AUC<jats:sub>0\u201324 h<\/jats:sub> and 0.95 (0.88, 1.01) and 0.95 (0.88, 1.01) for C<jats:sub>max<\/jats:sub>. In summary, coadministration of multiple\u2010dose taranabant 6 mg with oral contraceptives did not lead to clinically meaningful alterations in the pharmacokinetic profiles of ethinyl estradiol or norelgestromin.<\/jats:p>","DOI":"10.1177\/0091270008325930","type":"journal-article","created":{"date-parts":[[2008,10,21]],"date-time":"2008-10-21T00:54:35Z","timestamp":1224550475000},"page":"72-79","source":"Crossref","is-referenced-by-count":0,"title":["Influence of Taranabant, an Orally Active, Highly Selective, Potent Cannabinoid\u20101 Receptor (CB1R) Inverse Agonist, on Ethinyl Estradiol and Norelgestromin Plasma Pharmacokinetics"],"prefix":"10.1002","volume":"49","author":[{"given":"Jules I.","family":"Schwartz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Dunbar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinyu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susie","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah L.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Rosko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy O.","family":"Johnson\u2010Levonas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth C.","family":"Lasseter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,7]]},"reference":[{"key":"e_1_2_5_2_2","volume-title":"Obesity Fact Sheet","author":"World Health Organization.","year":"2008"},{"key":"e_1_2_5_3_2","volume-title":"Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report","author":"National Heart, Lung and Blood Institute.","year":"1998"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/346561a0"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/365061a0"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-6980(02)00060-6"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.2174\/187152706777452272"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00706.2002"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2007.11.012"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm060996"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.118737"},{"key":"e_1_2_5_12_2","first-page":"A326","article-title":"A two year study to assess the efficacy, safety, and tolerability of taranabant in obese patients: 52 week results","volume":"1021","author":"Gantz I","year":"2008","journal-title":"JACC"},{"key":"e_1_2_5_13_2","volume-title":"Ortho Tri\u2010cyclen Tablets (norgestimate\/ethinyl estradiol) [prescriber information]","year":"2007"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008314467"},{"key":"e_1_2_5_15_2","first-page":"A147","article-title":"Taranabant plama concentrations increased when co\u2010administered with ketoconazole or diltiazem","volume":"15","author":"Addy C","year":"2007","journal-title":"Obes Program Abstract Suppl"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008317591"},{"key":"e_1_2_5_17_2","first-page":"171","article-title":"Induction of sex hormone binding globulin (SHBG) by a single dose of norethindrone acetate\/ethinyl estradiol (NA\/EE)","volume":"61","author":"Boyd R","year":"1997","journal-title":"Clin Pharmacol Ther"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270008325930","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270008325930","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T23:07:48Z","timestamp":1697152068000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270008325930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["10.1177\/0091270008325930"],"URL":"https:\/\/doi.org\/10.1177\/0091270008325930","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}